Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.62 EUR -0.74%
Market Cap: 149.3m EUR

EV/EBITDA
Enterprise Value to EBITDA

-3.1
Current
-3.5
Median
6.4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-3.1
=
Enterprise Value
148.8m EUR
/
EBITDA
-48.4m EUR
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
FR
Innate Pharma SA
PAR:IPH
Average EV/EBITDA: 39.2
Negative Multiple: -3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
58.7
839%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.5
N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-13.6
2-Years Forward
EV/EBITDA
2.1
3-Years Forward
EV/EBITDA
1.5